TICKERNERD
Menu
PTNPTNHealthcare · Biotechnology

PTN Stock Forecast: Palatin Technologies, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$12
−1.83% on the day

The 3 Wall Street analysts covering Palatin Technologies, Inc. hold a median 12-month price target of $53 — +349.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$21.0M
Ticker Nerd rank
33 / 100
Median analyst target
$53
Analysts covering
3
Revenue$3.9M
Operating income−$1.6M
Net income−$1.4M
Free cash flow−$4.5M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.8%
1M
+59.2%
YTD
−23.3%
1Y
+37.4%
From 52W high
−57.9%
From 52W low
+105.2%
$6
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Palatin Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
97
Size
88
Volatility
61
Value
50
Momentum
41
Revisions
31
Issuance
18
Accruals
18
Quality
17

Growth (97): Sales and profits are climbing, and climbing faster than before.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26PTNHigh $60Median $53Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $48Median $53High $60

The green dot is the last close — the median target sits +349.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Dec 2025Laidlaw & Co.InitiatesBuy—
13 Feb 2025HC Wainwright & Co.MaintainsBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
24 Oct 2024HC Wainwright & Co.ReiteratesBuy—
20 June 2024HC Wainwright & Co.ReiteratesBuy—
12 June 2024HC Wainwright & Co.ReiteratesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
2 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.MaintainsBuy—
15 Feb 2024HC Wainwright & Co.ReiteratesBuy—
10 Aug 2023HC Wainwright & Co.ReiteratesBuy—
8 Aug 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.ReiteratesBuy—
30 May 2023HC Wainwright & Co.ReiteratesBuy—
9 May 2023HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PTN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Palatin Technologies, Inc. returned +37.4% against +17.5% for the S&P 500, dividends included.

PTN vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300Oct 25Jan 26Apr 26Jul 26PTNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PTN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Palatin Technologies, Inc. (PTN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
107.3×

Cheaper than 7% of US stocks

Price / sales
1.6×

Cheaper than 58% of US stocks

Price / book
2.0×

Cheaper than 46% of US stocks

EV / EBITDA
−1.3×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
3278.8%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−40.3%

Higher than 18% of US stocks

Net margin
−48.5%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−297.2%

Higher than 5% of US stocks

Return on assets
−65.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Palatin Technologies, Inc. (PTN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Palatin Technologies, Inc. has a market value of $21.0M and an enterprise value of $11.1M.

  • Revenue in the twelve months to 31 Mar 2026: $12.9M. The latest quarter grew 3278.8% year on year.

  • Net income over the same four quarters: −$6.2M, a −48.5% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$15.0M.

  • Shares outstanding: 1.8M.

  • Trailing P/E: 107.3×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Palatin Technologies, Inc. employs 29 people — $444K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

PTN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTNPalatin Technologies, Inc.$21.0M
33
NEUPNeuphoria Therapeutics, Inc.$20.1M
5
GRDXGridAI Technologies Corp.$20.3M
18
PBMPsyence Biomedical Ltd.$20.6M
4
ALLRAllarity Therapeutics, Inc.$19.6M
28
DYAIDyadic International, Inc.$19.4M
18
TCRXTScan Therapeutics, Inc.$20.9M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Palatin Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTN news & analysis

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Newsfile Corp · 6 Aug 2026neutral

The article highlights roughly $2.9 billion and $10.0 billion of recent acquisitions in the rare-endocrine space and notes that IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, posted $71.3 million in global second-quarter 2026 revenue, up 19% sequentially. It states that Palatin Technologies is developing the next generation of this drug class.

Why it matters — A PTN watcher would care because the article frames market demand and commercial traction for MC4R agonists, the drug class Palatin is developing.

FAQ

Frequently asked questions about PTN stock

What is the PTN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Palatin Technologies, Inc. have a median 12-month price target of $53, with estimates ranging from $48 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTN stock a buy right now?

Of the 3 analysts covering Palatin Technologies, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Palatin Technologies, Inc. 33 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTN?

As at 12 Sept 2026, Palatin Technologies, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).

Will PTN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +349.2% from the last close, and Ticker Nerd's factor model ranks Palatin Technologies, Inc. 33 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTN stock forecast for 2030?

No analyst covering Palatin Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $60 over the next 12 months.

How has PTN stock performed over the past year?

Palatin Technologies, Inc. returned +37.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Palatin Technologies, Inc. do?

Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system.

What is the latest news on PTN?

The most recent item we track (Newsfile Corp, 6 Aug 2026): "StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It". The article highlights roughly $2.9 billion and $10.0 billion of recent acquisitions in the rare-endocrine space and notes that IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, posted $71.3 million in global second-quarter 2026 revenue, up 19% sequentially. It states that Palatin Technologies is developing the next generation of this drug class.

Company

About Palatin Technologies, Inc.

Palatin Technologies Inc. is a biopharmaceutical company focused on developing first-in-class medicines that act on the melanocortin receptor system. Its current portfolio centers on receptor-targeted therapeutics for obesity, rare neuroendocrine disorders, inflammatory conditions, autoimmune diseases, and ocular disorders. The company’s work includes product candidates and partnered programs designed to address areas with significant unmet medical need, with a focus on selective peptide and small-molecule approaches. Palatin Technologies also participates in collaboration and licensing activities that support its research and development efforts across multiple therapeutic areas. Based in Princeton, New Jersey, Palatin Technologies Inc. operates as a clinical-stage company within the healthcare sector, where it contributes to the development of novel treatments aimed at specialized patient populations.

CEO Dr. Carl Spana Ph.D. · 29 employees · United States · https://palatin.com